FY2025 · ended Dec 31, 2025 · Revenue $9.68M, -92.8% YoY · Filed Feb 27, 2026
Prothena Corporation Public Limited Company (PRTA) files with the SEC under industry code 2834, Pharmaceutical Preparations. In fiscal 2025, which ended Dec 31, 2025, it reported revenue of $9.7 million and a net loss of $244.1 million. As of Jun 30, 2026 it held $288.2 million in cash and investments and $7.0 million in total debt.
Revenue (TTM)
$54.53M
+427.3% vs year-ago TTM
Net income (TTM)
$-43.99M
+85.5% vs year-ago TTM
Operating cash flow (TTM)
$-60.05M
+68.8% vs year-ago TTM
Free cash flow
—
EPS (TTM)
$-0.82
+85.4% vs year-ago TTM
Dividend per share
None
Shares outstanding
53.83M
+0.0% vs prior year
Net cash
$281.20M
as of Jun 30, 2026
Operating margin
-101.8%
FY 2026
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- PRTA (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- Ireland
- Headquarters
- Dublin 2, Ireland
- SEC filer status
- Accelerated filer
- SEC CIK
- 1559053
- Former names
- Prothena Corp plc (until May 22, 2020); Neotope Corp Ltd (until Oct 1, 2012)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $9.7M | $135.2M | $91.4M | $53.9M | $200.6M |
| Operating income | -$214.6M | -$154.6M | -$191.0M | -$131.6M | $72.0M |
| Net income | -$244.1M | -$122.3M | -$147.0M | -$116.9M | $67.0M |
| Diluted EPS | -$4.53 | -$2.27 | -$2.76 | -$2.47 | $1.38 |
| Operating cash flow | -$163.6M | -$150.1M | -$133.9M | -$108.8M | $92.6M |
| Total assets | $326.8M | $547.1M | $696.4M | $758.0M | $609.4M |
| Total liabilities | $46.3M | $60.2M | $135.0M | $136.0M | $143.3M |
| Stockholders' equity | $280.5M | $486.9M | $561.4M | $622.0M | $466.0M |
| Cash and investments | $307.5M | $471.4M | $618.8M | $710.4M | $579.1M |
| Total debt | $8.4M | $10.8M | $11.8M | $6.5M | $12.3M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Agreement ended
|
Oct 29, 2026 | Oct 28, 2026 |
| 8-K |
Current report
Officer or director change
|
Oct 2, 2026 | Oct 2, 2026 |
| 10-Q | Quarterly report | Aug 6, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 6, 2026 | Aug 6, 2026 |
| 8-K |
Current report
Shareholder vote results
|
May 15, 2026 | May 14, 2026 |
| 10-Q | Quarterly report | May 7, 2026 | Mar 31, 2026 |
All 1004 Prothena Corporation Public Limited Company SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.